Although conventional colonoscopy is considered the gold standard for detecting colorectal tumors, accurate staging is often difficult because advanced histology may be present in small colorectal lesions. We collected DNA present in mucosal wash fluid from patients undergoing colonoscopy and then assessed the methylation levels of four genes frequently methylated in colorectal cancers to detect invasive tumors. We found that methylation levels in wash fluid were significantly higher in patients with invasive than those with noninvasive tumors. Cytologic and K-ras mutation analyses suggested that mucosal wash fluid from invasive tumors contained greater numbers of tumor cells than wash fluid from noninvasive tumors. Among the four genes, levels of mir-34b/c methylation had the greatest correlation with the invasion and showed the largest area under the receiver operating characteristic curve (AUC = 0.796). Using cutoff points of mir-34b/c methylation determined by efficiency considerations, the sensitivity/specificity were 0.861/0.657 for the 13.0% (high sensitivity) and 0.765/0.833 for the 17.8% (well-balanced) cutoffs. In the validation test set, the AUC was also very high (0.915), the sensitivity/specificity were 0.870/0.875 for 13.0% and 0.565/0.958 for 17.8%. Using the diagnostic tree constructed by an objective algorithm, the diagnostic accuracy of the invasiveness of colorectal cancer was 91.3% for the training set and 85.1% for the test set. Our results suggest that analysis of the methylation of DNA in mucosal wash fluid may be a good molecular marker for predicting the invasiveness of colorectal tumors. Cancer Prev Res; 4(5); 674–83. ©2011 AACR.

Colorectal cancer is one of the most common neoplasias worldwide (1), and its early detection and accurate preoperative staging are essential for reducing the incidences of invasion and metastasis. The fecal occult blood test is widely used to screen for colorectal tumors, though its sensitivity and specificity are not high (2, 3). Conventional colonoscopy is considered the gold standard for detecting colorectal cancers and adenomas, whereas several other methods, including computed tomography, ultrasonography, and 3D magnetic resonance, have been used for staging (4, 5). Generally, tumor size is used as the marker for invasion and lymph node metastasis; however, accurate staging is often difficult because advanced histology may be present in as much as 10% of small (5–10 mm) colorectal adenomas (6–8).

Magnified endoscopy is a highly useful method for diagnosing invasive colorectal cancer (9, 10). Although conventional endoscopic examination with indigo carmine dye is not sufficient to determine whether or not a colorectal cancer is invasive, pit pattern analysis, using high-magnification observation with crystal violet, reportedly enables the diagnosis of invasive colorectal cancers. Recently, narrow-band imaging magnification endoscopy has also been used to predict the invasiveness of colorectal tumors (11). However, it has been suggested that the skills required for pit pattern analysis will limit the number of endoscopists who use the technique.

DNA methylation plays a critical role in the tumorigenesis of colorectal cancer (12, 13). For example, promoter hypermethylation is associated with the silencing of various cancer-related genes (14, 15), and aberrant methylation of the CpG islands of genes in stool and serum/plasma can be used as a molecular marker for detection of colorectal tumors (16–20). On the contrary, because DNA methylation is an early event (21–23), it does not enable one to distinguish between premalignant lesions and invasive tumors. As yet, there is no study describing a molecular test for predicting the invasiveness of colorectal tumors.

In this study, we examined the methylation levels of 4 genes frequently methylated in colorectal cancers by using DNA obtained from mucosal wash fluid. We found that the methylation level of DNA in the wash fluid was significantly higher in patients with invasive than those with noninvasive tumors. Our results suggest that methylation of DNA in mucosal wash fluid could be a good molecular marker for predicting the invasiveness of colorectal tumors.

Specimens and sample preparation

Colorectal tumor tissues and washing fluid were collected from Japanese patients who underwent endoscopic mucosal resection (EMR) or surgical resection of colorectal tumors at Akita Red Cross Hospital. Informed consent was obtained from all patients before collection of the specimens. Approval for this study was obtained from the Institutional Review Board of Akita Red Cross Hospital and Sapporo Medical University.

We used 2 methods to obtain DNA from mucosal washing fluid. When a colorectal tumor was detected during colonoscopy, the tumor's surface mucus was either washed away by using 20 mL of water, which was aspirated through the suction channel of the endoscope, and suspended in ThinPrep PreservCyt solution (Hologic, Inc.; method 1) or washed away with 20 mL of normal saline by using an NT tube and collected (method 2). Each sample of collected washing fluid was placed in a Non-GYN PreservCyt vial (Hologic, Inc.) for a minimum of 15 minutes, after which the solution was transferred to a disposable centrifuge tube and centrifuged at 500 × g for 20 minutes. The resultant supernatant was discarded, and the cell pellet was suspended in ThinPrep solution until DNA extraction. After collection of the washing fluid and endoscopic observation, biopsies of the colorectal tumor and corresponding normal colonic mucosa were carried out by using biopsy forceps under endoscopic guidance. For cytology analysis, a ThinPrep slide was prepared by a T2000 ThinPrep processor (Hologic, Inc.) and a nongynecologic ThinPrep Filter with 5-μm pores. The slide was then Papanicolaou stained and examined by GLab cytotechnologists and a pathologist (GeneticLab Co. Ltd.), and atypical cells were identified. Nuclei were stained by 4′,6-diamidino-2-phenylindole (DAPI) and visualized under a fluorescence microscope (Olympus) as described previously (24).

A total of 337 biopsy specimens including 150 colorectal tumors and 187 normal colonic mucosa specimens were examined. We also examined 88 samples of washing fluid from 70 colorectal tumor patients and 18 healthy patients. For testing the clinical usefulness of the study, we examined an additional 47 colorectal tumor biopsy samples as the test set, which were independently obtained several months after the collection of prior samples. On the basis of histologic examination after any type of resection, biopsy specimens and wash fluid samples from a colorectal tumor were divided into 2 groups: invasive tumors and noninvasive tumors. Invasive tumors were defined as submucosal invasive tumors.

Bisulfite pyrosequencing

DNA was extracted from biopsy specimens and washing fluid by using the standard phenol-chloroform procedure, after which 1-μg samples of genomic DNA were modified with sodium bisulfite by an EpiTect Bisulfite Kit (Qiagen). Bisulfite pyrosequencing was then carried out as described previously (25). Primers for pyrosequencing were designed by PSQ Assay Design software (Qiagen). Following PCR, the biotinylated PCR product was purified, made single-stranded, and then used as a template in a pyrosequencing reaction run according to the manufacturer's instructions. The PCR products were bound to streptavidin Sepharose beads HP (Amersham Biosciences), after which beads with the immobilized PCR product were purified, washed, and denatured by using a 0.2 mol/L NaOH solution. After addition of 0.3 μmol/L sequencing primer to the purified PCR product, pyrosequencing was carried out by a PSQ96MA system (Qiagen) and Pyro Q-CpG software (Qiagen). The primer sequences are listed in Supplementary Table S1.

K-ras mutation analysis

Mutation of codons 12 and 13 of K-ras was examined by using direct sequencing and pyrosequencing, as described previously (26). Pyrosequencing was done by a K-ras mutation detection kit (Qiagen) as suggested by the supplier.

Statistical analysis

All statistical analyses were carried out by SPSSJ 15.0 (SPSS Japan Inc.). To compare differences in methylation levels or other continuous values between groups, t tests or ANOVA with a post hoc Tukey test were carried out. Fisher's exact test was used for analysis of categorical data. To evaluate correlations between continuous values, Pearson's correlation coefficients were calculated. Receiver operating characteristic (ROC) curves for the diagnosis of invasive tumors were constructed on the basis of methylation levels, followed by area under the curve (AUC) calculation. A diagnostic tree to discriminate invasive tumors was constructed by using the training set based on the following objective algorithm. Step 1: classify the samples based on the most efficient cutoff of tumor size. Step 2: classify the samples based on the most efficient cutoffs of methylation levels in 4 sequences under the classification of the previous step. Step 3: repeat step 2 until no additional efficacy is observed. P < 0.05 (2-sided) were considered significant.

Preparation of specimens

We first compared the 2 methods used to obtain tumor cells from colonoscopy wash fluid. When tumors were found during colonoscopy, the tumor surfaces were washed with water (method 1) or saline (method 2; Supplementary Fig. S1A and B). Both methods enabled us to obtain enough DNA for molecular analysis (Table 1), but comparison of the cytology revealed that wash fluid obtained with saline (method 2) enabled more accurate detection of anaplastic cells (Supplementary Fig. S1B; Supplementary Table 1). We therefore used method 2 for subsequent analyses.

Table 1.

Amounts of DNA and quality of cytology obtained by using the 2 collection methods tested

Biopsy (n = 11)Wash fluid (method 1)Biopsy (n = 37)Wash fluid (method 2)
Total (n = 11)IT (n = 8)NI (n = 3)Total (n = 37)IT (n = 18)NI (n = 19)
DNA, μg 21.28 ± 15.25 15.00 ± 11.12   17.08 ± 13.00 16.53 ± 16.88   
Cytology         
 Diagnosable   17 11 
 Not diagnosable   20 13 
  18.2% 12.5% 33.3%  45.9% 61.1% 31.6% 
Biopsy (n = 11)Wash fluid (method 1)Biopsy (n = 37)Wash fluid (method 2)
Total (n = 11)IT (n = 8)NI (n = 3)Total (n = 37)IT (n = 18)NI (n = 19)
DNA, μg 21.28 ± 15.25 15.00 ± 11.12   17.08 ± 13.00 16.53 ± 16.88   
Cytology         
 Diagnosable   17 11 
 Not diagnosable   20 13 
  18.2% 12.5% 33.3%  45.9% 61.1% 31.6% 

Abbreviations: IT: invasive tumors, NI: noninvasive tumors.

DNA methylation in biopsy specimens

The clinical features of the patients examined in this study are summarized in Table 2. There was no statistically significant difference in age or gender between patients with invasive and noninvasive tumors. We selected 4 genes for analysis, mir-34b/c, SFRP1, SFRP2, and DKK2, which are frequently methylated in colorectal cancer (25, 27, 28). Methylation analysis was carried out by using bisulfite pyrosequencing with DNA from 337 specimens, including 52 invasive tumors, 98 noninvasive tumors, and 187 specimens of normal colon tissue. We found that the methylation levels of the 4 genes were significantly higher in cancerous tissue than in normal colorectal mucosa (Fig. 1); however, we found no difference in tissue methylation levels between invasive and noninvasive tumors.

Figure 1.

Levels of mir-34b/c, SFRP1, SFRP2, and DKK2 methylation in invasive and noninvasive colorectal tumors. Methylation levels detected with DNA from biopsy and wash fluid. The genes analyzed are shown on the left.

Figure 1.

Levels of mir-34b/c, SFRP1, SFRP2, and DKK2 methylation in invasive and noninvasive colorectal tumors. Methylation levels detected with DNA from biopsy and wash fluid. The genes analyzed are shown on the left.

Close modal
Table 2.

Clinicopathologic features of the patients

 Training setTest set
Biopsy sampleWashing fluidBiopsy sampleWashing fluid
IT (n = 52)NI (n = 98)PNormal (n = 187)IT (n = 36)NI (n = 34)PNormal (n = 18)IT (n = 20)NI (n = 21)PIT (n = 23)NI (n = 24)P
Demographics               
 Age 67.4 66.7 0.720 67.2 68.8 64.7 0.101 59.6 69.3 69.6 0.553 70.3 69.3 0.707 
 Male 16 (30.8%) 24 (24.5%)  126 (67.4%) 22 (61.1%) 25 (73.5%)  9 (50.0%) 14 (70%) 14 (66.7%)  14 (60.9%) 17 (70.8%)  
 Female 36 (69.2%) 74 (75.5%) 0.408 61 (32.6%) 14 (38.9%) 9 (26.5%) 0.269 9 (50.0%) 6 (30%) 7 (33.3%) 0.332 9 (39.1%) 7 (29.2%) 0.213 
Tumor size               
 ≥25 mm 31 (59.6%) 12 (12.2%)   27 (75%) 5 (14.7%)   15 (75%) 3 (14.3%)  18 (78.3%) 3 (12.5%)  
 <25 mm 21 (40.4%) 86 (87.8%) <0.001  9 (25%) 29 (85.3%) <0.001  5 (25%) 18 (85.7%) <0.001 5 (21.7%) 21 (87.5%) <0.001 
Location               
 Right 21 (40.4%) 44 (44.9%)   12 (33.3%) 17 (50%)   11 (55%) 12 (57.1%)  11 (47.8%) 13 (54.2%)  
 Left 15 (28.8%) 25 (25.5%)   14 (38.9%) 7 (20.6%)   7 (35%) 7 (33.3%)  8 (34.8%) 8 (33.3%)  
 Rectum 16 (30.8%) 29 (29.6%) 0.853  10 (27.8%) 10 (29.4%) 0.332  2 (10%) 2 (9.5%) 0.883 4 (17.4%) 3 (12.5%) 0.980 
Histology               
 Hyper/inflammatory  15 (15.3%)    3 (8.8%)    0 (0.0%)   0 (0.0%)  
 Tubular adenoma  29 (29.6%)    10 (29.4%)    9 (42.9%)   12 (50%)  
 Tubulovillous adenoma  28 (28.6%)    7 (20.6%)    7 (33.3%)   7 (29.2%)  
 Severe dysplasia  26 (26.5%)    14 (41.2%)    5 (23.8%)   5 (20.8%)  
 Cancer 52 (100.0%)    36 (100.0%)    20 (100.0%)   23 (100.0%)   
 Training setTest set
Biopsy sampleWashing fluidBiopsy sampleWashing fluid
IT (n = 52)NI (n = 98)PNormal (n = 187)IT (n = 36)NI (n = 34)PNormal (n = 18)IT (n = 20)NI (n = 21)PIT (n = 23)NI (n = 24)P
Demographics               
 Age 67.4 66.7 0.720 67.2 68.8 64.7 0.101 59.6 69.3 69.6 0.553 70.3 69.3 0.707 
 Male 16 (30.8%) 24 (24.5%)  126 (67.4%) 22 (61.1%) 25 (73.5%)  9 (50.0%) 14 (70%) 14 (66.7%)  14 (60.9%) 17 (70.8%)  
 Female 36 (69.2%) 74 (75.5%) 0.408 61 (32.6%) 14 (38.9%) 9 (26.5%) 0.269 9 (50.0%) 6 (30%) 7 (33.3%) 0.332 9 (39.1%) 7 (29.2%) 0.213 
Tumor size               
 ≥25 mm 31 (59.6%) 12 (12.2%)   27 (75%) 5 (14.7%)   15 (75%) 3 (14.3%)  18 (78.3%) 3 (12.5%)  
 <25 mm 21 (40.4%) 86 (87.8%) <0.001  9 (25%) 29 (85.3%) <0.001  5 (25%) 18 (85.7%) <0.001 5 (21.7%) 21 (87.5%) <0.001 
Location               
 Right 21 (40.4%) 44 (44.9%)   12 (33.3%) 17 (50%)   11 (55%) 12 (57.1%)  11 (47.8%) 13 (54.2%)  
 Left 15 (28.8%) 25 (25.5%)   14 (38.9%) 7 (20.6%)   7 (35%) 7 (33.3%)  8 (34.8%) 8 (33.3%)  
 Rectum 16 (30.8%) 29 (29.6%) 0.853  10 (27.8%) 10 (29.4%) 0.332  2 (10%) 2 (9.5%) 0.883 4 (17.4%) 3 (12.5%) 0.980 
Histology               
 Hyper/inflammatory  15 (15.3%)    3 (8.8%)    0 (0.0%)   0 (0.0%)  
 Tubular adenoma  29 (29.6%)    10 (29.4%)    9 (42.9%)   12 (50%)  
 Tubulovillous adenoma  28 (28.6%)    7 (20.6%)    7 (33.3%)   7 (29.2%)  
 Severe dysplasia  26 (26.5%)    14 (41.2%)    5 (23.8%)   5 (20.8%)  
 Cancer 52 (100.0%)    36 (100.0%)    20 (100.0%)   23 (100.0%)   

Abbreviations: IT: invasive tumors, NI: noninvasive tumors.

DNA methylation in mucosal washing fluid

We next examined gene methylation in 76 samples of mucosal wash fluid from 36 patients with invasive tumors and 34 with noninvasive tumors, and from 18 patients without colorectal lesions (Fig. 1). When we compared the invasive and noninvasive tumors, we found no differences for SFRP2 and DKK2. However, mir-34b/c and SFRP1 showed higher levels of methylation in wash fluid from patients with invasive than with noninvasive tumors.

We then used ROC analysis to further compare mucosal wash fluid from invasive and noninvasive tumors (Fig. 3A and B). The odds ratios (OR) for the risk of invasion associated with the methylation levels of the 4 genes tested are shown in Table 3. High levels of methylation were significantly associated with an increased risk of invasion. Among the 4 genes, levels of mir-34b/c methylation had the greatest impact on the risk of invasion and showed the largest AUC (0.796). Using various cutoff points of mir-34b/c methylation determined on the basis of efficiency considerations for clinical use, the sensitivity/specificity were 0.861/0.657 for the 13.0% (high sensitivity) cutoff point and 0.765/0.833 for the 17.8% (well balanced) cutoff. We also subdivided the tumors on the basis of whether they were ≥25 mm or <25 mm in size. In tumors 25 mm or larger, mir-34b/c showed the highest AUC (0.816); its sensitivity/specificity was 0.862/0.667 and its OR was 12.5. In tumors smaller than 25 mm, SFRP1 showed the highest AUC (0.810), with a sensitivity/specificity of 0.821/0.833 and an OR of 23.0.

Table 3.

Results of ROC analyses of the methylation levels in 4 genes in the training set.

Tumor sizeTraining set
GenesAUCCutoff (%)SensitivitySpecificityORs
Estimate (95% CI)Estimate (95% CI)Estimate (95% CI)Estimate (95% CI)
Total miR34b/c 0.796 (0.686–0.906) 13.0 0.861 (0.705–0.953) 0.647 (0.465–0.803) 11.4 (3.5–36.9) 
   17.8 0.833 (0.609–0.899) 0.765 (0.588–0.893) 16.3 (5.0–53.0) 
   21.0 0.611 (0.435–0.769) 0.882 (0.726–0.967) 11.8 (3.4–40.7) 
 SFRP1 0.736 (0.616–0.857) 45.0 0.750 (0.578–0.879) 0.706 (0.525–0.849) 7.2 (2.5–20.7) 
 SFRP2 0.688 (0.562–0.814) 33.0 0.583 (0.408–0.745) 0.765 (0.588–0.893) 4.5 (1.6–12.8) 
 DKK2 0.702 (0.572–0.831) 11.0 0.806 (0.64–0.918) 0.647 (0.465–0.803) 7.6 (2.6–22.5) 
≥25mm miR34b/c 0.816 (0.665–0.967) 15.0 0.862 (0.683–0.961) 0.667 (0.223–0.957) 12.5 (1.7–92.3) 
<25mm SFRP1 0.810 (0.594–1.000) 51.0 0.821 (0.631–0.939) 0.833 (0.359–0.996) 23.0 (2.2–242.1) 
Tumor sizeTraining set
GenesAUCCutoff (%)SensitivitySpecificityORs
Estimate (95% CI)Estimate (95% CI)Estimate (95% CI)Estimate (95% CI)
Total miR34b/c 0.796 (0.686–0.906) 13.0 0.861 (0.705–0.953) 0.647 (0.465–0.803) 11.4 (3.5–36.9) 
   17.8 0.833 (0.609–0.899) 0.765 (0.588–0.893) 16.3 (5.0–53.0) 
   21.0 0.611 (0.435–0.769) 0.882 (0.726–0.967) 11.8 (3.4–40.7) 
 SFRP1 0.736 (0.616–0.857) 45.0 0.750 (0.578–0.879) 0.706 (0.525–0.849) 7.2 (2.5–20.7) 
 SFRP2 0.688 (0.562–0.814) 33.0 0.583 (0.408–0.745) 0.765 (0.588–0.893) 4.5 (1.6–12.8) 
 DKK2 0.702 (0.572–0.831) 11.0 0.806 (0.64–0.918) 0.647 (0.465–0.803) 7.6 (2.6–22.5) 
≥25mm miR34b/c 0.816 (0.665–0.967) 15.0 0.862 (0.683–0.961) 0.667 (0.223–0.957) 12.5 (1.7–92.3) 
<25mm SFRP1 0.810 (0.594–1.000) 51.0 0.821 (0.631–0.939) 0.833 (0.359–0.996) 23.0 (2.2–242.1) 

We further verified the utility of DNA methylation in mucosal washing, using an independent set of specimens, which was established as the test set (Figs. 2, 3C and D; Table 4). All of these ROC analyses were considered the training set. In the test set, the methylation levels of mir-34b/c showed very high AUC again (0.915), sensitivity/specificity was 0.870/0.875 for the 13.0% cutoff, and 0.565/0.958 for the 17.8% cutoff. In tumors 25 mm or larger, the AUC of the methylation levels of mir-34b/c was 0.778. In tumors smaller than 25 mm, the AUC of the methylation levels of SFRP1 was 0.695.

Figure 2.

Methylation levels of mir-34b/c, SFRP1, SFRP2, and DKK2 in the test set. Methylation levels detected with DNA from biopsy tissues and wash fluid. The genes analyzed are shown on the left.

Figure 2.

Methylation levels of mir-34b/c, SFRP1, SFRP2, and DKK2 in the test set. Methylation levels detected with DNA from biopsy tissues and wash fluid. The genes analyzed are shown on the left.

Close modal
Figure 3.

ROC curve analysis. ROC curves were constructed by plotting sensitivity vs. 1-specificity. Curves are shown comparing invasive vs. noninvasive tumors. AUCs are also shown in the graphs. A and B, ROC curve analysis for the training set. Overall analysis is shown in A, and stratified analysis by tumor size (≥25 mm or <25 mm) is shown in B. C and D, the same analysis for the test set. Overall analysis is shown in C, and that stratified by tumor size (≥25 mm or <25 mm) is shown in D.

Figure 3.

ROC curve analysis. ROC curves were constructed by plotting sensitivity vs. 1-specificity. Curves are shown comparing invasive vs. noninvasive tumors. AUCs are also shown in the graphs. A and B, ROC curve analysis for the training set. Overall analysis is shown in A, and stratified analysis by tumor size (≥25 mm or <25 mm) is shown in B. C and D, the same analysis for the test set. Overall analysis is shown in C, and that stratified by tumor size (≥25 mm or <25 mm) is shown in D.

Close modal
Table 4.

Results of ROC analyses of the methylation levels in 4 genes in the test set.

Test set
AUCCutoff (%)SensitivitySpecificityORs
Tumor sizeGenesEstimate (95% CI)Estimate (95% CI)Estimate (95% CI)Estimate (95% CI)
Total miR34b/c 0.915 (0.833–0.997) 13.0 0.870 (0.664–0.972) 0.875 (0.676–0.973) 46.7 (8.4–258.9) 
   17.8 0.565 (0.345–0.768) 0.958 (0.789–0.999) 29.9 (3.4–260.6) 
   21.0 0.348 (0.164–0.573) 1.000 (0.858–1.000) N/A 
 SFRP1 0.752 (0.615–0.889) 45.0 0.348 (0.164–0.573) 0.875 (0.676–0.973) 3.7 (0.8–16.4) 
≥25mm miR34b/c 0.778 (0.000–1.000) 15.0 0.667 (0.410–0.867) 0.667 (0.094–0.991) 4.0 (0.3–53.5) 
<25mm SFRP1 0.695 (0.450–0.941) 51.0 0.200 (0.005–0.716) 1.000 (0.839–1.000) N/A 
Test set
AUCCutoff (%)SensitivitySpecificityORs
Tumor sizeGenesEstimate (95% CI)Estimate (95% CI)Estimate (95% CI)Estimate (95% CI)
Total miR34b/c 0.915 (0.833–0.997) 13.0 0.870 (0.664–0.972) 0.875 (0.676–0.973) 46.7 (8.4–258.9) 
   17.8 0.565 (0.345–0.768) 0.958 (0.789–0.999) 29.9 (3.4–260.6) 
   21.0 0.348 (0.164–0.573) 1.000 (0.858–1.000) N/A 
 SFRP1 0.752 (0.615–0.889) 45.0 0.348 (0.164–0.573) 0.875 (0.676–0.973) 3.7 (0.8–16.4) 
≥25mm miR34b/c 0.778 (0.000–1.000) 15.0 0.667 (0.410–0.867) 0.667 (0.094–0.991) 4.0 (0.3–53.5) 
<25mm SFRP1 0.695 (0.450–0.941) 51.0 0.200 (0.005–0.716) 1.000 (0.839–1.000) N/A 

To make a more efficient diagnostic method suitable for clinical situations, we then constructed a diagnostic tree to classify invasive and noninvasive tumors on the basis of the combination of methylation levels detected in wash fluid (Fig. 4A). First, because most endoscopists make an endoscopic diagnosis according to the size of lesions, we defined the most efficient cutoff of tumor size as the first node of the diagnostic tree. As the next nodes, we used the most efficient cutoffs of the methylation levels of the 4 genes (mir-34, SFRP1, SFRP2, and DKK2). For example, as shown in Figure 4A, if the tumor size is more than 25 mm and the methylation level of mir-34b/c is more than 15%, this lesion is diagnosed as an invasive tumor. In the training set, the sensitivity and specificity were 0.943 (33/35) and 0.882 (30/34), respectively. The total accuracy of the diagnosis was 91.3% (63/69). For use in clinical situations, we validated this diagnostic tree by using an independent test set (n = 47). The application of the diagnostic tree to the test set is shown in Figure 4B. Although a slight reduction in sensitivity was observed (0.740, 17/23), the specificity was very high (0.958, 21/24). The total accuracy of the diagnosis was 85.1% (40/47) for the test set.

Figure 4.

A diagnostic tree to classify invasive and noninvasive tumors on the basis of methylation levels detected in wash fluid. A, a diagnostic tree constructed on the basis of the training set. The majority class in each leaf is the predictive class. B, the application of the diagnostic tree to the test set.

Figure 4.

A diagnostic tree to classify invasive and noninvasive tumors on the basis of methylation levels detected in wash fluid. A, a diagnostic tree constructed on the basis of the training set. The majority class in each leaf is the predictive class. B, the application of the diagnostic tree to the test set.

Close modal

We also assessed the correlation between methylation levels detected in biopsy specimens and in wash fluid (Supplementary Fig. S2). We found that overall methylation levels in biopsy tissues and washing fluid were well correlated. When we divided the data for invasive and noninvasive tumors, however, only invasive tumors showed a significant correlation between methylation levels in biopsy tissue and washing fluid.

Detection of K-ras mutation by mucosal washing fluid

Finally, we tested for mutation of K-ras codons 12 and 13 by using DNA obtained from biopsy tissue or wash fluid (Supplementary Table S2). With invasive tumors, mutations of K-ras were found in 9 of 27 (33.3%) biopsy specimens. Among the 9 positive tumors, we were able to also detect mutations in 7 (77.7%) wash fluid samples. With noninvasive tumors, mutations were detected in 6 of 24 (25%) biopsy specimens, but in only 2 (33.3%) of the corresponding wash fluid samples. Addition of K-ras mutation did not improve the accuracy of diagnosis of invasiveness by the diagnostic tree (data not shown). Consistent with this finding, nuclear staining showed more intact nuclei in wash fluid from invasive tumors than from noninvasive tumors (Supplementary Fig. S1C). Thus, samples from invasive tumors seem to contain higher concentrations of tumor-derived DNA than samples from noninvasive tumors.

Small colorectal tumors are usually removed by endoscopic mucosal dissection, but if the tumor is invasive, surgical treatment is required because of the higher risk of lymph node metastasis. Consequently, precise preoperative diagnosis is critical for appropriate treatment of colorectal tumors. Magnifying colonoscopy is a useful means of distinguishing invasive from noninvasive tumors (9, 10). However, invasive colorectal tumors show a heterogeneous pit pattern, making it difficult to determine a therapeutic strategy based on pit pattern diagnosis alone (29). Notably, surface mucus is washed away during magnifying endoscopic analysis, so that utilization of the wash fluid could be an effective noninvasive approach to diagnosis. It has been recommended that nearly all colorectal cancer patients who receive EMR receive periodic endoscopy for early detection of relapses (30). Examination of the methylation levels in the wash fluid could provide helpful information as to how often the patient should receive the follow-up endoscopy (e.g., the lower the methylation level, the less frequently endoscopic examination may be needed). In addition, although we did not include follow-up in our study, it is possible that wash fluid analysis could help physicians detect mucosal relapse after EMR during follow-up endoscopy.

It has been reported that DNA methylation in wash fluid containing pancreatic juice, saliva, or gastric juice is useful for diagnosis and risk assessment in cancer (34–36). For example, Watanabe and colleagues reported that DNA methylation in gastric wash fluid is useful for detection of early gastric cancer (36). The unique feature of our study is that it suggests DNA methylation in colon mucosal wash fluid can be used to predict the invasiveness of tumors. Further study will be necessary to determine whether DNA methylation of colon mucosal wash might also be useful for screening or risk assessment in cancer.

Here we showed that levels of mir-34b/c gene methylation were predictive of the invasiveness of colorectal tumors (Figs. 3 and 4; Tables 3 and 4). The sensitivity (0.833) and specificity (0.765) of this approach (well balanced cutoff), as well as the ROC AUC value (0.796), suggest methylation of this gene in colonoscopic wash fluid is a good molecular marker that distinguishes invasive from noninvasive colorectal tumors. We also showed that a diagnostic tree constructed by the combination of methylation levels was highly accurate for predicting invasiveness. To avoid unneeded surgery, it is important that the prediction of invasiveness is highly specific. In this regard, the specificities of the diagnostic tree were 0.882 in the training set, and 0.958 in the test set.

There is currently no molecular test that distinguishes invasive from noninvasive colorectal tumors. DNA methylation can be used as a biomarker for detection of colorectal lesions (16–20), but genes frequently methylated in cancer are also frequently methylated in early lesions (e.g., adenomas), and even in normal colorectal mucosa from aged patients (21, 22). It is therefore difficult to distinguish invasive tumors from noninvasive ones. We previously showed that SFRP1 and SFRP2 are frequently methylated in colorectal cancer (28). However, they are also often methylated in normal colorectal mucosa in an age-related manner (34), which is consistent with our present findings. The mir-34b/c gene is a putative tumor suppressor whose expression is induced by p53 (35). We previously showed that mir-34b/c is silenced by DNA methylation in colorectal cancers and adenomas (25). In this study, we found that methylation of mir-34b/c in noninvasive tumors is as high as that in invasive tumors. By contrast, levels of mir-34b/c methylation in normal colorectal mucosa are low. Thus, given the high frequency of methylation in tumors, tumor-specific methylation of mir-34b/c may be a highly useful molecular marker for colorectal cancer.

The molecular mechanism underlying the high levels of DNA methylation in wash fluid from invasive tumors is not fully understood. Analysis of nuclear staining, DNA methylation, and K-ras mutation suggest that wash fluid–derived DNA from invasive tumors contains higher concentrations of tumor-derived DNA than wash fluid from noninvasive tumors. It is generally accepted that colonic epithelial cells are exfoliated into the lumen, that cancer cells can be detected among stool-derived exfoliated cells, and that stool DNA/RNA derived from exfoliated cells may be useful for diagnosis (36, 37). In that context, there are several possible explanations for the higher concentration of DNA from invasive tumor cells in colonoscopy wash fluid. Resistance to apoptosis and loss of cell adhesion are characteristic features of invasive cells (38, 39), which may facilitate the survival of exfoliated cells allowing for good DNA quality. Although we did not detect high levels of methylation in wash fluid from noninvasive tumors, we did obtain relatively large amounts of DNA. The origin of the DNA remains to be determined, but it may be derived from both tumor cells and normal cells such as white blood cells.

Our findings suggest that the high levels of mir-34b/c methylation in invasive tumors could be applied to predict invasiveness by using stool DNA. To date, most diagnostic methods for detecting colorectal tumors based on DNA methylation utilize qualitative methylation analysis (16, 19, 20). Using sensitive and quantitative analysis such as BEAMing technology (18), it should be possible to predict the invasiveness of tumors by using stool DNA. Further study to optimize the threshold will be necessary, however.

In summary, high levels of DNA methylation in colorectal washing fluid were correlated with invasiveness of colorectal lesions. Combining endoscopic and DNA methylation analyses may facilitate accurate preoperative staging of colorectal cancer.

No potential conflicts of interest were disclosed.

The authors thank Dr. William F. Goldman for editing the manuscript.

This study was supported in part by Grants-in-Aid for Scientific Research on Priority Areas (T. Tokino, K. Imai, and M. Toyota), Grants-in-Aid for Scientific Research (S) from the Japan Society for Promotion of Science (K. Imai), a Grant-in-Aid for the Third-term Comprehensive 10-year Strategy for Cancer Control (M. Toyota), and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare, Japan (M. Toyota).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Jemal
A
,
Siegel
R
,
Ward
E
,
Hao
Y
,
Xu
J
,
Murray
T
, et al
Cancer statistics, 2008
.
CA Cancer J Clin
2008
;
58
:
71
96
.
2.
Davies
RJ
,
Miller
R
,
Coleman
N
. 
Colorectal cancer screening: prospects for molecular stool analysis
.
Nat Rev Cancer
2005
;
5
:
199
209
.
3.
Osborn
NK
,
Ahlquist
DA
. 
Stool screening for colorectal cancer: molecular approaches
.
Gastroenterology
2005
;
128
:
192
206
.
4.
Kwok
H
,
Bissett
IP
,
Hill
GL
. 
Preoperative staging of rectal cancer
.
Int J Colorectal Dis
2000
;
15
:
9
20
.
5.
Yamada
I
,
Okabe
S
,
Enomoto
M
,
Sugihara
K
,
Yoshino
N
,
Tetsumura
A
, et al
Colorectal carcinoma: in vitro evaluation with high-spatial-resolution 3D constructive interference in steady-state MR imaging
.
Radiology
2008
;
246
:
444
53
.
6.
Hurlstone
DP
,
Cross
SS
,
Adam
I
,
Shorthouse
AJ
,
Brown
S
,
Sanders
DS
, et al
A prospective clinicopathological and endoscopic evaluation of flat and depressed colorectal lesions in the United Kingdom
.
Am J Gastroenterol
2003
;
98
:
2543
9
.
7.
Kudo
S
,
Kashida
H
,
Tamura
T
,
Kogure
E
,
Imai
Y
,
Yamano
H
, et al
Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer
.
World J Surg
2000
;
24
:
1081
90
.
8.
Soetikno
R
,
Friedland
S
,
Kaltenbach
T
,
Chayama
K
,
Tanaka
S
. 
Nonpolypoid (flat and depressed) colorectal neoplasms
.
Gastroenterology
2006
;
130
:
566
76
;
quiz 88–9
.
9.
Bianco
MA
,
Rotondano
G
,
Marmo
R
,
Garofano
ML
,
Piscopo
R
,
de Gregorio
A
, et al
Predictive value of magnification chromoendoscopy for diagnosing invasive neoplasia in nonpolypoid colorectal lesions and stratifying patients for endoscopic resection or surgery
.
Endoscopy
2006
;
38
:
470
6
.
10.
Matsuda
T
,
Fujii
T
,
Saito
Y
,
Nakajima
T
,
Uraoka
T
,
Kobayashi
N
, et al
Efficacy of the invasive/non-invasive pattern by magnifying chromoendoscopy to estimate the depth of invasion of early colorectal neoplasms
.
Am J Gastroenterol
2008
;
103
:
2700
6
.
11.
Kanao
H
,
Tanaka
S
,
Oka
S
,
Hirata
M
,
Yoshida
S
,
Chayama
K
. 
Narrow-band imaging magnification predicts the histology and invasion depth of colorectal tumors
.
Gastrointest Endosc
2009
;
69
:
631
6
.
12.
Markowitz
SD
,
Bertagnolli
MM
. 
Molecular origins of cancer: Molecular basis of colorectal cancer
.
N Engl J Med
2009
;
361
:
2449
60
.
13.
Wong
JJ
,
Hawkins
NJ
,
Ward
RL
. 
Colorectal cancer: a model for epigenetic tumorigenesis
.
Gut
2007
;
56
:
140
8
.
14.
Issa
JP
. 
CpG island methylator phenotype in cancer
.
Nat Rev Cancer
2004
;
4
:
988
93
.
15.
Jones
PA
,
Baylin
SB
. 
The epigenomics of cancer
.
Cell
2007
;
128
:
683
92
.
16.
Glöckner
SC
,
Dhir
M
,
Yi
JM
,
McGarvey
KE
,
Van Neste
L
,
Louwagie
J
, et al
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer
.
Cancer Res
2009
;
69
:
4691
9
.
17.
Hellebrekers
DM
,
Lentjes
MH
,
van den Bosch
SM
,
Melotte
V
,
Wouters
KA
,
Daenen
KL
, et al
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer
.
Clin Cancer Res
2009
;
15
:
3990
7
.
18.
Li
M
,
Chen
WD
,
Papadopoulos
N
,
Goodman
SN
,
Bjerregaard
NC
,
Laurberg
S
, et al
Sensitive digital quantification of DNA methylation in clinical samples
.
Nat Biotechnol
2009
;
27
:
858
63
.
19.
Müller
HM
,
Oberwalder
M
,
Fiegl
H
,
Morandell
M
,
Goebel
G
,
Zitt
M
, et al
Methylation changes in faecal DNA: a marker for colorectal cancer screening?
Lancet
2004
;
363
:
1283
5
.
20.
Zou
HZ
,
Yu
BM
,
Wang
ZW
,
Sun
JY
,
Cang
H
,
Gao
F
, et al
Detection of aberrant p16 methylation in the serum of colorectal cancer patients
.
Clin Cancer Res
2002
;
8
:
188
91
.
21.
Ahuja
N
,
Li
Q
,
Mohan
AL
,
Baylin
SB
,
Issa
JP
. 
Aging and DNA methylation in colorectal mucosa and cancer
.
Cancer Res
1998
;
58
:
5489
94
.
22.
Issa
JP
,
Ottaviano
YL
,
Celano
P
,
Hamilton
SR
,
Davidson
NE
,
Baylin
SB
. 
Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon
.
Nat Genet
1994
;
7
:
536
40
.
23.
Park
SJ
,
Rashid
A
,
Lee
JH
,
Kim
SG
,
Hamilton
SR
,
Wu
TT
. 
Frequent CpG island methylation in serrated adenomas of the colorectum
.
Am J Pathol
2003
;
162
:
815
22
.
24.
Satoh
A
,
Toyota
M
,
Itoh
F
,
Sasaki
Y
,
Suzuki
H
,
Ogi
K
, et al
Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer
.
Cancer Res
2003
;
63
:
8606
13
.
25.
Toyota
M
,
Suzuki
H
,
Sasaki
Y
,
Maruyama
R
,
Imai
K
,
Shinomura
Y
, et al
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer
.
Cancer Res
2008
;
68
:
4123
32
.
26.
Kusano
M
,
Toyota
M
,
Suzuki
H
,
Akino
K
,
Aoki
F
,
Fujita
M
, et al
Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus
.
Cancer
2006
;
106
:
1467
79
.
27.
Sato
H
,
Suzuki
H
,
Toyota
M
,
Nojima
M
,
Maruyama
R
,
Sasaki
S
, et al
Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors
.
Carcinogenesis
2007
;
28
:
2459
66
.
28.
Suzuki
H
,
Watkins
DN
,
Jair
KW
,
Schuebel
KE
,
Markowitz
SD
,
Chen
WD
, et al
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer
.
Nat Genet
2004
;
36
:
417
22
.
29.
Tanaka
S
,
Kaltenbach
T
,
Chayama
K
,
Soetikno
R
. 
High-magnification colonoscopy (with videos)
.
Gastrointest Endosc
2006
;
64
:
604
13
.
30.
Winawer
SJ
,
Zauber
AG
,
Fletcher
RH
,
Stillman
JS
,
O'Brien
MJ
,
Levin
B
, et al
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society
.
Gastroenterology
2006
;
130
:
1872
85
.
31.
Matsubayashi
H
,
Canto
M
,
Sato
N
,
Klein
A
,
Abe
T
,
Yamashita
K
, et al
DNA methylation alterations in the pancreatic juice of patients with suspected pancreatic disease. Cancer Res
2006
;
66
:
1208
17
.
32.
Pattani
KM
,
Zhang
Z
,
Demokan
S
,
Glazer
C
,
Loyo
M
,
Goodman
S
, et al
Endothelin receptor type B gene promoter hypermethylation in salivary rinses is independently associated with risk of oral cavity cancer and premalignancy. Cancer Prev Res
2010
;
3
:
1093
103
.
33.
Watanabe
Y
,
Kim
HS
,
Castoro
RJ
,
Chung
W
,
Estecio
MR
,
Kondo
K
, et al
Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology
2009
;
136
:
2149
58
.
34.
Shen
L
,
Toyota
M
,
Kondo
Y
,
Lin
E
,
Zhang
L
,
Guo
Y
, et al
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer
.
Proc Natl Acad Sci U S A
2007
;
104
:
18654
9
.
35.
He
L
,
He
X
,
Lim
LP
,
de Stanchina
E
,
Xuan
Z
,
Liang
Y
, et al
A microRNA component of the p53 tumour suppressor network
.
Nature
2007
;
447
:
1130
4
.
36.
White
V
,
Scarpini
C
,
Barbosa-Morais
NL
,
Ikelle
E
,
Carter
S
,
Laskey
RA
, et al
Isolation of stool-derived mucus provides a high yield of colonocytes suitable for early detection of colorectal carcinoma
.
Cancer Epidemiol Biomarkers Prev
2009
;
18
:
2006
13
.
37.
Zhao
C
,
Ivanov
I
,
Dougherty
ER
,
Hartman
TJ
,
Lanza
E
,
Bobe
G
, et al
Noninvasive detection of candidate molecular biomarkers in subjects with a history of insulin resistance and colorectal adenomas
.
Cancer Prev Res
2009
;
2
:
590
7
.
38.
Brown
JM
,
Attardi
LD
. 
The role of apoptosis in cancer development and treatment response
.
Nat Rev Cancer
2005
;
5
:
231
7
.
39.
Christofori
G
. 
Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression
.
EMBO J
2003
;
22
:
2318
23
.